Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, IIPR, FTAI, and Revance and Encourages Investors to Contact the FirmNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (
NASDAQBIOA), Innovative Industrial Properties, Inc.
NYSE:IIPRNYSEIIPR)
(NASDAQ:FTAINASDAQFTAI
, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025NEW YORK - March 1, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Rosen Law Firm Urges Revance Therapeutics, Inc. (NASDAQ: RVNC) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Revance Therapeutics, Inc. (
NASDAQRVNC) between February 29, 2024 and December 6, 2024. Revance describes itself as a “biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.”
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025NEW YORK - February 28, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
RVNC DEADLINE ALERT: Kirby McInerney LLP Alerts Revance Therapeutics, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit
The law firm of Kirby McInerney LLP alerts investors of the imminent March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) securities between February 29, 2024, through December 6, 2024 (“the Class Period”). The firm encourages investors to contact the firm as soon as possible to be appointed lead plaintiff.
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan FoxNEW YORK - February 27, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan FoxNEW YORK - February 27, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025NEW YORK - February 26, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025NEW YORK - February 25, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Nextracker, FTAI, and Revance and Encourages Investors to Contact the FirmNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (
NASDAQBIOA), Nextracker Inc.
NASDAQ:NXTNASDAQNXT)
(NASDAQ:FTAINASDAQFTAI
, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (
NASDAQRVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025NEW YORK - February 17, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025NEW YORK - February 15, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan FoxNEW YORK - February 14, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025NEW YORK - February 13, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (
NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
